Literature DB >> 26714815

Left Ventricular Tonic Contraction as a Novel Biomarker of Cardiomyopathy in Duchenne Muscular Dystrophy.

Jennifer A Su1,2, Leigh Ramos-Platt3,4, JonDavid Menteer5,3.   

Abstract

Dilated cardiomyopathy (DCM) inevitably afflicts patients with Duchenne muscular dystrophy (DMD) as a consequence of cell death induced by unguarded calcium influx into cardiomyocytes. This mechanism may also inhibit muscle relaxation in early stages of cardiomyopathy. ACE inhibition (ACEi) is known to delay the onset and slow the progression of DCM in DMD. The objective of this study is to use echocardiography to assess for preclinical cardiac changes consistent with intracellular calcium dysregulation before the onset of overt ventricular dysfunction, and to evaluate how prophylactic ACEi may alter these pre-cardiomyopathic changes in the pediatric DMD population. We examined 263 echocardiograms from 70 pediatric patients with DMD. We defined abnormal tonic contraction (TC) as left ventricular internal dimension in diastole (LVIDd) Z-score < -1.5. In our cohort, we found that TC is detectable as early as 8 years of age, and most commonly affects patients between 11 and 15 years. This effect was independent of LV mass and systolic function. Prophylactic ACEi decreased the incidence of TC (p = 0.007) and preserved cardiac function (p < 0.0001). Left ventricular TC often precedes DCM in DMD, most commonly affecting the 11- to 15-year-old age range. TC is not related to ventricular hypertrophy, but rather may be a clinical correlate of the "calcium hypothesis" of DMD pathophysiology. LV TC is thus a promising biomarker for early detection of cardiomyopathy in DMD. ACEi prophylaxis suppresses LV TC and delays the development of DCM in DMD.

Entities:  

Keywords:  ACE inhibition; Biomarker; Dilated cardiomyopathy; Duchenne muscular dystrophy; Pediatrics; Prophylaxis

Mesh:

Substances:

Year:  2015        PMID: 26714815     DOI: 10.1007/s00246-015-1331-1

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  24 in total

1.  Alterations in dihydropyridine receptors in dystrophin-deficient cardiac muscle.

Authors:  Peter J Woolf; Sai Lu; Renee Cornford-Nairn; Michael Watson; Xiao-Hui Xiao; Sean M Holroyd; Lindsay Brown; Andrew J Hoey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-01-13       Impact factor: 4.733

2.  Hemodynamic effects of a single oral dose of enalapril among children with asymptomatic chronic mitral regurgitation.

Authors:  R Calabrò; C Pisacane; G Pacileo; M G Russo
Journal:  Am Heart J       Date:  1999-11       Impact factor: 4.749

3.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

Review 4.  How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes.

Authors:  J M Alderton; R A Steinhardt
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

5.  Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy.

Authors:  Ralf Bauer; Volker Straub; Alison Blain; Kate Bushby; Guy A MacGowan
Journal:  Eur J Heart Fail       Date:  2009-02-20       Impact factor: 15.534

6.  All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.

Authors:  Gernot Schram; Anne Fournier; Hugues Leduc; Nagib Dahdah; Johanne Therien; Michel Vanasse; Paul Khairy
Journal:  J Am Coll Cardiol       Date:  2013-01-23       Impact factor: 24.094

7.  Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.

Authors:  Jacob E Møller; Ulf Dahlström; Ole Gøtzsche; Avijit Lahiri; Knud Skagen; Gert Steen Andersen; Kenneth Egstrup
Journal:  Am Heart J       Date:  2004-03       Impact factor: 4.749

8.  Relative vs. absolute values: using patient and population norms for echocardiography in pediatric cardiac transplant recipients.

Authors:  Katherine K Raczek; Frederick Dorey; Pierre C Wong; Jacqueline R Szmuszkovicz; Jondavid Menteer
Journal:  Pediatr Transplant       Date:  2009-04-07

9.  Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.

Authors:  Venus Ameen; Lesley G Robson
Journal:  Open Cardiovasc Med J       Date:  2010-11-26

10.  Heterogeneous abnormalities of in-vivo left ventricular calcium influx and function in mouse models of muscular dystrophy cardiomyopathy.

Authors:  Elizabeth Greally; Benjamin J Davison; Alison Blain; Steve Laval; Andrew Blamire; Volker Straub; Guy A MacGowan
Journal:  J Cardiovasc Magn Reson       Date:  2013-01-16       Impact factor: 5.364

View more
  6 in total

1.  Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells.

Authors:  J Manuel Pioner; Xuan Guan; Jordan M Klaiman; Alice W Racca; Lil Pabon; Veronica Muskheli; Jesse Macadangdang; Cecilia Ferrantini; Michael R Hoopmann; Robert L Moritz; Deok-Ho Kim; Chiara Tesi; Corrado Poggesi; Charles E Murry; Martin K Childers; David L Mack; Michael Regnier
Journal:  Cardiovasc Res       Date:  2020-02-01       Impact factor: 10.787

2.  Troponin I Levels Correlate with Cardiac MR LGE and Native T1 Values in Duchenne Muscular Dystrophy Cardiomyopathy and Identify Early Disease Progression.

Authors:  Sonia Voleti; Laura Olivieri; Karin Hamann; Heather Gordish-Dressman; Christopher Spurney
Journal:  Pediatr Cardiol       Date:  2020-05-31       Impact factor: 1.655

3.  Early-Onset Late Gadolinium Enhancement is a Prognostic Factor for Duchenne Cardiomyopathy.

Authors:  Lorraine James; Jondavid Menteer; Lilith C Moss; Ramon Durazo-Arvizu; John C Wood; Leigh Ramos-Platt; Emmanuelle Tiongson; Jennifer A Su
Journal:  Pediatr Cardiol       Date:  2022-09-03       Impact factor: 1.838

4.  The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts.

Authors:  H Lee Sweeney; Stefano Masiero; Ugo Carraro
Journal:  Eur J Transl Myol       Date:  2022-03-10

Review 5.  Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.

Authors:  Takeshi Tsuda; Kristi K Fitzgerald
Journal:  J Cardiovasc Dev Dis       Date:  2017-09-08

Review 6.  The multifaceted view of heart problem in Duchenne muscular dystrophy.

Authors:  Urszula Florczyk-Soluch; Katarzyna Polak; Józef Dulak
Journal:  Cell Mol Life Sci       Date:  2021-06-06       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.